Product Images Gemcitabine
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Gemcitabine NDC 25021-239 by Sagent Pharmaceuticals, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
gem0a 0007 01
gem0a 0007 02
gem0a 0007 03
This text appears to be discussing a comparison of documented disease progression between two treatments over a certain period. It includes information about the number of months for each treatment group (Paciiaxel 29 months) and presents statistical results (Log rank p 00001) indicating a significant difference. The study involves a comparison of Gemcitabine/Paciiaxel treatment with a group of 267 participants. The x-axis appears to be "Time to Documented Disease Progression (Months)."*
gem0a 0007 04
This text provides information on survival rates related to Gem/Cis and Cisplatin treatments. The median survival times are 9.0 months for Gem/Cis and 7.6 months for Cis. The text also mentions survival probabilities but includes incomplete data. Overall, this document serves as a guide for understanding survival outcomes for cancer patients undergoing these treatments.*
gem0a 0007 05
gem0a 0007 06
gem0a 0007 07
gem0a 0007 08
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
